1-11 of 11
Tom Moore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

Michael Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, Harriet S Walter, David Carlile, Nicole Getzmann, Samira Curdt, Emma Harrop, Abiraj Keelara, Koorosh Korfi, Remi Labatut, Francesca Michielin, Sarah Louise Mycroft, Tom Moore, Robert Nutbrown, Giuseppe Palldino, Matt Whayman, Johannes Sam, Martin Weisser, Katharina E Lechner, Franck Morschhauser, Martin Hutchings
Journal: Blood
Blood (2022) 140 (Supplement 1): 3818–3820.
https://doi.org/10.1182/blood-2022-156808
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Martin Hutchings, MD PhD, Fritz C. Offner, MD PhD, Francesc Bosch, MD PhD, Giuseppe Gritti, MD PhD, Carmelo Carlo-Stella, MD, Harriet Walter, William Townsend, MRCP,MDFRCPath, Franck Morschhauser, MD PhD, Guillaume Cartron, MD PhD, Hervé Ghesquieres, MD PhD, Sophie de Guibert, MD, Sylvia Herter, PhD, Koorosh Korfi, PhD, Veronica Craine, Sarah Louise Mycroft, Matt Whayman, Claudia Mueller, Natalie Dimier, PhD, Tom Moore, MBChB, Sara Belli, Martin Kornacker, MD, Katharina Lechner, Michael Dickinson, DMed Sci
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-136571
Published: 2020
Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1584.
https://doi.org/10.1182/blood-2019-123949
Published: 2019
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt
Journal: Blood
Blood (2019) 134 (Supplement_1): 2871.
https://doi.org/10.1182/blood-2019-123978
Published: 2019
Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3799.
https://doi.org/10.1182/blood-2019-123712
Published: 2019
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5319.
https://doi.org/10.1182/blood-2019-123979
Published: 2019
Journal Articles

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Franck Morschhauser, MD, Fritz Offner, MD, Anna Sureda, MD, Gilles Andre Salles, MD PhD, Carmelo Carlo-Stella, MD, Joaquin Martinez Lopez, MD, Denise Thomas, BS, Peter N Morcos, PhD, Betsy Quackenbush, MD, Cristiano Ferlini, MD, Marina Bacac, PhD, Ann-Marie E. Broeske, PhD, Natalie Dimier, PhD, Tom Moore, MD, Martin Weisser, MD, Michael Dickinson, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 226.
https://doi.org/10.1182/blood-2018-99-110207
Published: 2018
Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2016) 128 (22): 6.
https://doi.org/10.1182/blood.V128.22.6.6
Published: 2016
Journal Articles

Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study

Stephan Stilgenbauer, MDPhD, Osman Ilhan, Darius Woszczyk, Christoph Renner, Eva Mikuskova, Sebastian Böttcher, MD, Eugen Tausch, MD, Tom Moore, Nicola Tyson, Helena Adamis, Véronique Leblonde, Francesc Bosch, Robin Foà
Journal: Blood
Blood (2015) 126 (23): 493.
https://doi.org/10.1182/blood.V126.23.493.493
Published: 2015
Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB
Journal: Blood
Blood (2013) 122 (21): 5612.
https://doi.org/10.1182/blood.V122.21.5612.5612
Published: 2013